GLP-1 Drugs Multiply Brain Connections Within Months in 13-Patient Scan Study
Updated
Updated · The Washington Post · May 28
GLP-1 Drugs Multiply Brain Connections Within Months in 13-Patient Scan Study
9 articles · Updated · The Washington Post · May 28
Brain scans of 13 teens and young women on GLP-1 drugs showed extensive changes within months, including multiplied connections in the salience network that helps direct attention.
Scientists said they did not expect the effect and still do not know whether the drugs act directly in the brain or indirectly through reduced inflammation, better metabolism and gut-brain signaling.
Early research is widening beyond weight loss and diabetes to addiction, mood, cognition and neurodegeneration, with trials underway for alcohol-use disorder, long Covid symptoms and other conditions.
Some patients report quieter cravings and less "food noise," but others describe brain fog, emotional flattening and reduced motivation, raising questions about whether dampened reward circuits could also alter healthy desire.
With tens of millions now taking Ozempic, Wegovy and related medicines, researchers say the drugs have become a vast real-world test of how metabolic treatments may reshape the brain.
Beyond weight loss, are these drugs permanently rewiring our brains and changing who we are as people?
These drugs quiet 'food noise,' but what essential human desires and pleasures are they silencing along with it?
The GLP-1 Revolution: Profound Brain, Mood, and Behavior Changes in 12% of U.S. Adults—Risks, Rewards, and Unknowns
Overview
Recent scientific investigations show that GLP-1 medications, such as those used for weight loss, can rapidly and profoundly influence the brain. These drugs are not only helping people feel full even before eating, but are also actively rewiring brain circuits involved in satiety, behavior, and emotions. Scientists have identified specific brain regions responsible for these effects, and found that GLP-1 drugs can enhance cognitive function by activating certain receptors and signaling pathways. This leads to changes in how people experience fullness, motivation, and emotional states, highlighting the complex and far-reaching impact of GLP-1 drugs on the brain.